Cargando…

MON-592 Early and More Frequent Monitoring of Thyroid Function Tests (TFTs) Post-RAI Could Be Clinically Beneficial

Background: Radioiodine (RAI) is widely used for the treatment of hyperthyroidism. Most patients respond to RAI therapy with a normalization of TFTs and improvement in clinical symptoms within 4-8 weeks. Hypothyroidism may occur from 4 weeks on, with 40% of patients being hypothyroid by 8 weeks and...

Descripción completa

Detalles Bibliográficos
Autores principales: Aljenaee, Khaled, Ali, Sulaiman, Cooke, Jennie, Phelan, Niamh, Pazderska, Agnieszka, Healy, Marie Louise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550720/
http://dx.doi.org/10.1210/js.2019-MON-592
_version_ 1783424245904179200
author Aljenaee, Khaled
Ali, Sulaiman
Cooke, Jennie
Phelan, Niamh
Pazderska, Agnieszka
Healy, Marie Louise
author_facet Aljenaee, Khaled
Ali, Sulaiman
Cooke, Jennie
Phelan, Niamh
Pazderska, Agnieszka
Healy, Marie Louise
author_sort Aljenaee, Khaled
collection PubMed
description Background: Radioiodine (RAI) is widely used for the treatment of hyperthyroidism. Most patients respond to RAI therapy with a normalization of TFTs and improvement in clinical symptoms within 4-8 weeks. Hypothyroidism may occur from 4 weeks on, with 40% of patients being hypothyroid by 8 weeks and >80% by 16 weeks. American thyroid association guidelines recommend testing for free T4, total T3, and TSH within the first 1-2 months after RAI. Biochemical monitoring should be continued at 4- to 6-week intervals for 6 months, or until the patient becomes hypothyroid and stable on thyroid replacement therapy. Our local protocol is to monitor thyroid function more frequently and earlier, week 1,3,6,9,12,24 post RAI therapy to avoid any delay in starting treatment if required. Methods: 79 patients with hyperthyroidism underwent definiive treatment with RAI between January 2012 and June 2017. Monitoring of thyroid function tests were examined retrospectively to determine timing of initiation of treatment for either hypothyroidism or persistent hyperthyroidism post RAI. Results: Treatment started for both hypothyroidism and persistent hyperthyroidism in 47/79 patients, 41 developed hypothyroidism while 6 became hyperthyroid. 19/41 developed hypothyroidism within 9 weeks post RAI, while 9/41 developed hypothyroid within 3 weeks post RAI. Median time to commence treatment was 13.6 weeks. Conclusion: Frequent early monitoring of thyroid function tests post RAI may avoid delay in starting treatment for patients developing either hypo- or hyperthyroidism.
format Online
Article
Text
id pubmed-6550720
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65507202019-06-13 MON-592 Early and More Frequent Monitoring of Thyroid Function Tests (TFTs) Post-RAI Could Be Clinically Beneficial Aljenaee, Khaled Ali, Sulaiman Cooke, Jennie Phelan, Niamh Pazderska, Agnieszka Healy, Marie Louise J Endocr Soc Thyroid Background: Radioiodine (RAI) is widely used for the treatment of hyperthyroidism. Most patients respond to RAI therapy with a normalization of TFTs and improvement in clinical symptoms within 4-8 weeks. Hypothyroidism may occur from 4 weeks on, with 40% of patients being hypothyroid by 8 weeks and >80% by 16 weeks. American thyroid association guidelines recommend testing for free T4, total T3, and TSH within the first 1-2 months after RAI. Biochemical monitoring should be continued at 4- to 6-week intervals for 6 months, or until the patient becomes hypothyroid and stable on thyroid replacement therapy. Our local protocol is to monitor thyroid function more frequently and earlier, week 1,3,6,9,12,24 post RAI therapy to avoid any delay in starting treatment if required. Methods: 79 patients with hyperthyroidism underwent definiive treatment with RAI between January 2012 and June 2017. Monitoring of thyroid function tests were examined retrospectively to determine timing of initiation of treatment for either hypothyroidism or persistent hyperthyroidism post RAI. Results: Treatment started for both hypothyroidism and persistent hyperthyroidism in 47/79 patients, 41 developed hypothyroidism while 6 became hyperthyroid. 19/41 developed hypothyroidism within 9 weeks post RAI, while 9/41 developed hypothyroid within 3 weeks post RAI. Median time to commence treatment was 13.6 weeks. Conclusion: Frequent early monitoring of thyroid function tests post RAI may avoid delay in starting treatment for patients developing either hypo- or hyperthyroidism. Endocrine Society 2019-04-30 /pmc/articles/PMC6550720/ http://dx.doi.org/10.1210/js.2019-MON-592 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Thyroid
Aljenaee, Khaled
Ali, Sulaiman
Cooke, Jennie
Phelan, Niamh
Pazderska, Agnieszka
Healy, Marie Louise
MON-592 Early and More Frequent Monitoring of Thyroid Function Tests (TFTs) Post-RAI Could Be Clinically Beneficial
title MON-592 Early and More Frequent Monitoring of Thyroid Function Tests (TFTs) Post-RAI Could Be Clinically Beneficial
title_full MON-592 Early and More Frequent Monitoring of Thyroid Function Tests (TFTs) Post-RAI Could Be Clinically Beneficial
title_fullStr MON-592 Early and More Frequent Monitoring of Thyroid Function Tests (TFTs) Post-RAI Could Be Clinically Beneficial
title_full_unstemmed MON-592 Early and More Frequent Monitoring of Thyroid Function Tests (TFTs) Post-RAI Could Be Clinically Beneficial
title_short MON-592 Early and More Frequent Monitoring of Thyroid Function Tests (TFTs) Post-RAI Could Be Clinically Beneficial
title_sort mon-592 early and more frequent monitoring of thyroid function tests (tfts) post-rai could be clinically beneficial
topic Thyroid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550720/
http://dx.doi.org/10.1210/js.2019-MON-592
work_keys_str_mv AT aljenaeekhaled mon592earlyandmorefrequentmonitoringofthyroidfunctionteststftspostraicouldbeclinicallybeneficial
AT alisulaiman mon592earlyandmorefrequentmonitoringofthyroidfunctionteststftspostraicouldbeclinicallybeneficial
AT cookejennie mon592earlyandmorefrequentmonitoringofthyroidfunctionteststftspostraicouldbeclinicallybeneficial
AT phelanniamh mon592earlyandmorefrequentmonitoringofthyroidfunctionteststftspostraicouldbeclinicallybeneficial
AT pazderskaagnieszka mon592earlyandmorefrequentmonitoringofthyroidfunctionteststftspostraicouldbeclinicallybeneficial
AT healymarielouise mon592earlyandmorefrequentmonitoringofthyroidfunctionteststftspostraicouldbeclinicallybeneficial